IP Library Granted Patent US 7,385,040
Granted Patent B2
US 7,385,040 · App. 10/589,718 · Granted Jun 10, 2008

Antibody purification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,385,040
App. No.
10/589,718
Granted
Jun 10, 2008
Kind
B2
Abstract

The present invention relates to a method of separating antibodies from contaminants in a solution, which method comprises contacting the solution with a chromatography resin comprised of a support to which multi-modal ligands have been immobilised, wherein a multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system. In one embodiment, the ring-forming atoms of the aromatic or hereoaromatic entity are selected among C, S or O, and the cation exchanging group is a weak cation exchanger. The present method may be used as a single step procedure or as a polishing step following a capture on a Protein A column.

Claims (8)

1. A method of separating antibodies from one or more contaminants in a solution, comprising contacting the solution, which is an antibody-containing eluate from an affinity chromatography resin, with a second chromatography resin comprised of a support to which multi-modal ligands have been immobilised, wherein a multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system, to adsorb antibodies and/or contaminants to the resin.

2. The method of claim 1 , wherein the ring-forming atoms of the hereoaromatic ring system are selected from the group consisting of C, S or O.

3. The method of claim 1 , wherein the cation-exchanging group is a weak cation exchanger.

4. The method of claim 1 , wherein the contaminants comprise complexes formed between released affinity ligands and antibodies, and/or aggregates of released affinity ligands and/or antibodies.

5. The method of claim 1 , wherein the contaminants are adsorbed to the second chromatography resin.

6. The method of claim 1 , further comprising eluting antibodies and/or contaminants from the second chromatography resin.

7. The method of claim 1 , wherein the antibodies are monoclonal antibodies.

8. The method of claim 1 , wherein the solution is an antibody-containing eluate from an affinity chromatography resin the ligands of which comprise Protein A.

Assignments (4)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2006
From: JOHANSSON, BO-LENNART; JOHANSSON, HANS J.; LJUNGLOF, ANDERS; MALOISEL, JEAN-LUC; THEVENIN, NICOLAS
To: AMERSHAM BIOSCIENCES AB
Reel/Frame 018169/0432 →
CHANGE OF NAME Recorded Aug 25, 2006
From: AMERSHAM BIOSCIENCES AB
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 018169/0526 →